用息性放射治疗治疗的患者的预后方法:叙述性综述
Rachel F Shenker1, Niema B Razavian2, Claire M Lanier2
1Department of Radiation Oncology, Duke University Hospital, Durham, NC, USA.
Annals of palliative medicine
|December 21, 2023
概括
息性放射治疗 (PRT) 评分系统有助于临床医生预测患者的预后. 这些工具指导选择最佳的,个性化的PRT方案,以平衡症状控制和生活质量.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 临床决策支持 临床决策支持
背景情况:
- 息性放射治疗 (PRT) 的实践模式在瘤学家之间有所不同.
- 选择PRT疗法需要平衡症状控制与患者的生活质量.
研究的目的:
- 对息性放射治疗的预后评分系统进行审查.
- 帮助临床决策者选择合适的PRT疗法.
主要方法:
- 在PubMed搜索2000年1月1日至2023年7月2日之间发表的文章.
- 包括英语,同行评审的文章,介绍PRT预后评分系统.
- 使用的关键词:缓解,放射治疗,生存.
主要成果:
- 对于PRT存在多种预后模型,根据特定的患者群体和瘤类型量身定制.
- 模型结合了临床特征 (例如,主要部位,性能状态,转移性疾病) 来估计整体存活率 (OS).
- 评分系统根据估计的生存率为不同PRT疗法指导推.
结论:
- PRT评分系统帮助临床医生评估患者的预后.
- 这一审查使放射瘤学家能够创建个性化的PRT治疗计划.
- 改善预后评估导致更好地定制的息性放射治疗.
相关概念视频
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Radiological Investigation III: Pulmonary Angiogram and PET Scan
93
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
93
Kaplan-Meier Approach
149
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
149


